Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma

WVT078 administered with and without WHG626 showed a manageable safety profile. Preliminary activity was observed in patients with r/r MM. The addition of WHG626 numerically improved response over WVT078 monotherapy. Findings from this study support further evaluation of WHG626 as a combination partner of BCMA-targeting agents for r/r MM treatment.